# Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors

Study · id `cardio:ct-nct07077525` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07077525](<https://clinicaltrials.gov/study/NCT07077525>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07077525

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

## Technical summary

Registry record NCT07077525. Randomized; no masking; primary purpose treatment. Start 2023-06-01 (actual); primary completion 2024-08-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 196 participants (enrolled count; ClinicalTrials.gov record NCT07077525, source copy `cardio:ctgov-nct07077525-2025-07-22`, retrieved 2026-10-26)
- Started: 2023-06-01 (actual) (ClinicalTrials.gov record NCT07077525, source copy `cardio:ctgov-nct07077525-2025-07-22`, retrieved 2026-10-26)
- Primary completion: 2024-08-10 (actual) (ClinicalTrials.gov record NCT07077525, source copy `cardio:ctgov-nct07077525-2025-07-22`, retrieved 2026-10-26)
- Completion: 2024-08-31 (actual) (ClinicalTrials.gov record NCT07077525, source copy `cardio:ctgov-nct07077525-2025-07-22`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT07077525, source copy `cardio:ctgov-nct07077525-2025-07-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07077525-2025-07-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors
- Condition: Type 2 Diabetes
- Intervention (Combination product): Dapagliflozin + Metformin
- Intervention (Combination product): Vildagliptin + Metformin
- Lead sponsor: Al-Azhar University
- Lead sponsor class: OTHER
- Collaborator: General Committee of Teaching Hospitals and Institutes, Egypt
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 6cb7c1bca31d06618a46f295c63729c56cfd4e6ac3eef91793596e89796a6f16
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
